WHY WAS THIS FUNDED?

The NCI regularly contracts with outside companies to run scientific and administrative operations at its research facilities, particularly at the Frederick National Laboratory for Cancer Research in Maryland. Additional program information is not available on the specific legal authority cited for this award.

WHAT PUBLIC PROBLEM IS IT TRYING TO SOLVE?

Cancer is one of the leading causes of death in the United States, and the NCI needs day-to-day operational support to keep its research programs running. This contract helps ensure that cancer research labs and programs continue to function without interruption.

WHO BENEFITS?

Researchers, scientists, and staff at NCI facilities benefit directly, as do cancer patients and the broader public who may eventually benefit from the research these operations support. Workers employed by Leidos Biomedical Research also benefit through jobs funded by this contract.

WHAT ARE THE RISKS?

Because the contract type is listed as unknown and the award is very large, there is limited public information available to assess whether the work is being competitively bid or fairly priced. Large sole-source or cost-reimbursement contracts can sometimes be harder to hold accountable for efficiency and value to taxpayers.

WHAT HAPPENS IF FUNDING IS REMOVED?

If this contract were cancelled, the day-to-day operations of NCI research facilities could be disrupted or shut down, delaying cancer research projects. Staff supported by the contract could lose their jobs, and ongoing scientific work could be set back by months or longer.

ARGUMENTS FOR

• •Cancer research requires continuous operational support, and this contract helps ensure that important scientific work at one of the world's leading cancer research institutions keeps moving forward.
• •Leidos Biomedical Research has a long history of managing NCI operations, meaning this funding supports experienced staff who already understand the complex work involved.
• •Advances in cancer treatment and prevention that come from NCI research can benefit millions of Americans, making the operational investment potentially cost-effective over time.

ARGUMENTS AGAINST

• •At nearly $338 million for a single year, this is an extremely large contract, and the lack of information about contract type makes it difficult for the public to know whether taxpayers are getting competitive pricing.
• •Relying heavily on one private contractor to run a major government research institute raises questions about whether critical public health functions should be managed in-house instead.
• •The title 'operational task order' provides very little detail about what specific services are being paid for, making it hard for citizens or oversight bodies to evaluate whether the spending is justified.